Clinical trial · Interventional
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma. PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific cytotoxic T cells in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes | Biological | — | UNRESOLVED |
| fludarabine phosphate | Drug | Fludarabine | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven Hodgkin's lymphoma * Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation * Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER) * Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria: * EBV seropositive * HIV negative * HTLV-1 negative * Hepatitis B surface antigen and hepatitis B core antibody IgM negative * Hepatitis C antibody negative * Must share at least 1 HLA haplotype with donor PATIENT CHARACTERISTICS: Age: * 18 to 75 Performance status: * Not specified Life expectancy: * At least 8 weeks Hematopoietic: * Not specified Hepatic: * Bilirubin less than 2.0 mg/dL * SGOT/SGPT less than 2.5 times normal (unless liver metastases are present) * If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required * No hepatic dysfunction causing moribundity Renal: * Creatinine clearance greater than 50 mL/min * No renal dysfunction causing moribundity Cardiovascular: * No cardiac dysfunction causing moribundity Pulmonary: * No pulmonary dysfunction causing moribundity Other: * No neurologic dysfunction causing moribundity * No history of severe transfusion reactions with blood products (including fetal calf serum) * Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: * See Disease Characteristics Chemotherapy: * See Disease Characteristics * No concurrent antimetabolites Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics Surgery: * Not specified
References
Publications (1)
- RESULTLucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004 May 1;100(9):1892-901. doi: 10.1002/cncr.20188. PMID 15112270